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Abstract
Background: Neuromyelitis optica spectrum disorder (NMOSD) and multiple sclerosis (MS) have a similar clinical
phenotype but represent distinct diseases, requiring different therapies. MicroRNAs (miRNAs) are short non-coding RNAs
whose expression profiles can serve as diagnostic biomarkers and which may be involved in the pathophysiology of
neuroinflammatory diseases. Here, we analyzed miRNA profiles in serum and whole blood of patients with NMOSD and
clinically isolated syndrome (CIS)/relapsing-remitting MS (RRMS) as well as healthy controls by next-generation
sequencing (NGS).
Methods: MiRNA expression profiles were determined by NGS in sera of patients with aquaporin-4 antibody-positive
NMOSD (n = 20), CIS/RRMS (n = 20), and healthy controls (n = 20) and in whole blood of patients with NMOSD (n = 11),
CIS/RRMS (n = 60), and healthy controls (n = 43). Differentially expressed miRNAs were calculated by analysis of variance
and t tests. All significance values were corrected for multiple testing. Selected miRNAs were validated in whole blood
of patients with NMOSD (n = 18) and CIS/RRMS (n = 19) by quantitative real-time polymerase chain reaction (qRT-PCR).
Results: None of 261 miRNAs detected in serum but 178 of 416 miRNAs detected in whole blood showed significantly
different expression levels among the three groups. Pairwise comparisons revealed 115 (NMOSD vs. CIS/RRMS), 141
(NMOSD vs. healthy controls), and 44 (CIS/RRMS vs. healthy controls) miRNAs in whole blood with significantly different
expression levels. qRT-PCR confirmed different expression levels in whole blood of patients with NMOSD and CIS/RRMS
for 9 out of 10 exemplarily chosen miRNAs. In silico enrichment analysis demonstrated an accumulation of altered
miRNAs in NMOSD in particular in CD15+ cells (i.e., neutrophils and eosinophils).
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Conclusions: This study identifies a set of miRNAs in whole blood, which may have the potential to discriminate
NMOSD from CIS/RRMS and healthy controls. In contrast, miRNA profiles in serum do not appear to be promising
diagnostic biomarkers for NMOSD. Enrichment of altered miRNAs in CD15+ neutrophils and eosinophils, which
were previously implicated in the pathophysiology of NMOSD, suggests that miRNAs could be involved in the
regulation of these cells in NMOSD.
Keywords: Neuromyelitis optica spectrum disorder, Multiple sclerosis, MicroRNAs, Biomarker, Whole blood,
Serum, Next-generation sequencing
Background
Neuromyelitis optica (NMO) was formerly considered a
variant of multiple sclerosis (MS) [1, 2]. However, the dis-
covery of a highly specific serum autoantibody against the
aquaporin-4 (AQP4) water channel, which is present in
60–80 % of patients with NMO, clarified that NMO is a
separate disease pathophysiologically distinct from MS
[3–5]. While the classical NMO phenotype consists of a
longitudinally extensive transverse myelitis (LETM) and
optic neuritis (ON), AQP4 antibody-positive patients can
also present with isolated LETM, ON, or brainstem en-
cephalitis. This spectrum of clinical manifestations is now
referred to as NMO spectrum disorder (NMOSD) [5, 6].
Because the clinical phenotype of NMOSD and MS may
be similar, but each condition requires different therapeutic
approaches, accurate differentiation of NMOSD and MS is
highly relevant [7]. Although magnetic resonance imaging
and AQP4 antibody testing aid in the differential diagnosis,
misdiagnosis of NMOSD with MS is not infrequent [8, 9]
and reliable biomarkers that distinguish between both en-
tities would be desirable.
MicroRNAs (miRNAs) are single-stranded, short (20–24
nucleotide) regulatory RNAs that regulate gene expression
at the posttranscriptional level. MiRNAs are present in
stable form in the human blood, and blood-based miRNA
expression profiles may hold promise as diagnostic bio-
markers in various human diseases, including cancer and
autoimmune diseases [10]. Indeed, studies performed by
others and our group indicate that miRNA expression pro-
files determined either in whole blood or purified blood cell
subtypes could play a role as potential biomarkers for MS
[11–25]. Furthermore, miRNAs circulating in plasma were
recently shown to be differentially expressed in different
stages of MS (relapsing-remitting MS (RRMS) vs. second-
ary progressive MS) and were thus proposed as an easily
accessible blood-based biomarker to monitor MS [26].
MiRNA profiles have hitherto not been investigated in
NMOSD and their role in the differentiation of NMOSD,
and MS has not been explored so far. A possible role of
miRNAs in the pathophysiology of NMOSD likewise
remains elusive. We here report the results of a systematic
comparative analysis of miRNA profiles in serum and
whole blood of patients with NMOSD and clinically
isolated syndrome (CIS)/RRMS as well as healthy controls
using next-generation sequencing.
Methods
Ethics, consent, and permissions
The study was performed in accordance with the
Declaration of Helsinki and was approved by the in-
stitutional review board, Charité—Universitätsmedizin
Berlin, (EA1/131/09). All participants provided written
informed consent.
Serum and whole blood samples of patients and healthy
controls
Between May and November 2013, serum (collected in
Sarstedt serum tubes [REF 02.1063]; Sarstedt, Nürm-
brecht, Germany) and whole blood samples (collected in
PAXgene Blood RNA tubes; Becton Dickinson, Heidel-
berg, Germany) were obtained by peripheral venipuncture
of a total of 20 patients with NMOSD (age >18 years), pre-
senting with LETM and ON (n = 11), LETM and brainstem
encephalitis (n = 3), isolated LETM (n = 4), or isolated ON
(n = 2). All patients with NMOSD had serum antibodies to
AQP4 as determined by a cell-based assay [27]. Serum and
whole blood samples were likewise obtained from a total of
44 participants of an ongoing prospective observational
study of patients with early MS (Berlin CIS cohort,
NCT01371071), which started recruitment in January 2011.
Inclusion criteria were age >18 years, a first clinical event
suggestive of central nervous system demyelination (CIS)
not meeting the McDonald 2010 criteria for RRMS [28]
within 6 months before study inclusion, or a diagnosis of
RRMS according to the McDonald 2010 criteria within
24 months before study inclusion. To increase the number
of whole blood miRNA profiles of patients with CIS/RRMS,
we additionally used miRNA profiles of 16 further patients
with CIS/RRMS obtained in a previous project, in which
exactly the same methodology as in the present work was
applied [25]. In addition, serum samples were also collected
from 20 healthy controls. Furthermore, we included whole
blood miRNA profiles of a total of 43 healthy controls
obtained in two previous projects (n = 21 from Keller et al.
[25] and n = 22 from Leidinger et al. [29]), in which, again,
exactly the same methodology as in the present work was
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applied. Except for the 22 healthy control samples from
Leidinger et al. [29], which were purchased from Preci-
sionMed (San Diego, CA, USA), all patients with NMOSD
and CIS/RRMS and healthy controls were recruited at the
Department of Neurology and NeuroCure Clinical Re-
search Center, Charité—Universitätsmedizin Berlin. Serum
and whole blood samples were withdrawn in parallel and
processed at the NeuroCure Clinical Research Center ac-
cording to standard operating procedures and stored at
−80 °C. Coded serum samples were shipped on dry ice to
the Department of Internal Medicine III, Heidelberg Uni-
versity, and coded whole blood samples were shipped on
dry ice to the Department of Human Genetics, Saarland
University, for further blinded processing.
RNA isolation from serum
The mirVANA PARIS Kit Ambion (AM1556) was used to
isolate RNA from 200 μl of serum. In addition to the man-
ufacturer’s protocol, precipitation was also performed
using 2 M ammonium acetate. To gain sufficient amounts
of miRNA, the isolation procedure was performed twice
and eluates were pooled.
Library preparation and next-generation sequencing of
serum samples
For the library preparation, 6 μl of the eluates from the
serum RNA isolation was used. Preparation was performed
following the protocol of the TruSeq Small RNA Sample
Prep Kit (Illumina). To reduce adapter dimerization, we
only used half the amount of adapters during preparation.
Concentration of the ready prepped libraries was measured
on the Bioanalyzer using the High Sensitivity Chip. Librar-
ies were then pooled in batches of six samples in equal
amounts and clustered with a concentration of 18 pmol in
one lane each of a single read flowcell using the cBot (Illu-
mina). Sequencing of 50 cycles was performed on a HiSeq
2000 (Illumina). Demultiplexing of the raw sequencing
data and generation of the fastq files were done using
CASAVA v.1.8.2.
RNA isolation from whole blood and next-generation
sequencing of whole blood samples
Total RNA including miRNA was isolated from whole
blood samples using the PAXgene Blood miRNA Kit
(Qiagen, Hilden, Germany), and next-generation sequen-
cing was performed on a HiSeq2000 System (Illumina)
exactly as previously described in detail [25].
Quantitative real-time polymerase chain reaction
Quantitative real-time polymerase chain reaction (qRT-
PCR) on whole blood was performed using the miScript
PCR System according to the manufacturer’s recommen-
dations (Qiagen). Samples included in the qRT-PCR study
were analyzed as individual and not as pooled samples.
For whole blood samples, the small RNA RNU48 was used
as endogenous control for normalization according to the
ΔCt method [30]. The mean ± standard deviation Ct value
of RNU48 of the 37 samples analyzed was 19.89 ± 0.78.
Bioinformatics analysis
For matching raw NGS reads to miRNAs, the miR-
Deep algorithm was applied [31]. Subsequent calcula-
tions were carried out using the freely available statistical
programming environment R (version 3.0.2). To make
NGS raw read counts more comparable, standard quantile
normalization was used as implemented in the normalize.-
quantiles function. Analysis of variance (ANOVA) was
carried out by the anova function. Pairwise t tests were
carried out using the t.test function. Adjustment for mul-
tiple testing was performed by controlling the false discov-
ery rate according to the approach of Benjamini and
Hochberg. Besides t tests, the area under the receiver op-
erator characteristic curve (AUC value) was computed to
determine how well the miRNAs separate between two
groups. Box and whisker plots were generated by using
the boxplot function. For calculating volcano plots, the
log2 of the mean expression was calculated and plotted
against the log10 p value (raw p values were used for this
purpose). Different expression levels in the qRT-PCR ana-
lysis were assessed by t test and Mann-Whitney test. Gen-
der distribution between the groups of patients with
NMOSD, CIS/RRMS, and healthy controls was assessed
by a 3 × 2 Fisher’s exact test. Age differences between
groups were assessed by Kruskal-Wallis or Mann-Whitney
test. Moreover, the miRNACon tool (freely available at
http://www.ccb.uni-saarland.de/mirnacon/) was applied in
order to identify miRNAs that are potentially influenced
by age or gender [32]. Finally, we used our tool miEAA
(http://www.ccb.uni-saarland.de/mieaa_tool/) to further
characterize the association of sets of miRNAs with path-
ways, functional categories, diseases, tissues, or cell types.
MiEAA is based on GeneTrail [33] and performs standard
enrichment analyses like over-representation analysis or
gene set enrichment analysis in the context of miRNAs.
This way, we identify significantly enriched miRNA
categories where we find more miRNAs in our input set
than expected by chance. If not mentioned otherwise,
adjusted p values <0.05 were considered significant.
Results
Participants
Demographic and clinical characteristics of patients with
NMOSD, CIS/RRMS, and healthy controls studied in
the different parts of this work are summarized in
Table 1. All NMOSD patients were in remission at the
time of sampling, and no one had experienced a relapse
within the prior 4 months. There were no significant dif-
ferences in the gender distributions between the various
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groups in the different analyses. However, patients with
NMOSD were significantly older than patients with CIS/
RRMS, which is in accordance with the higher median
age at onset in AQP4-IgG-positive NMOSD compared
to MS [5] and healthy controls in the serum NGS study.
Furthermore, healthy controls were significantly older
than patients with NMOSD and CIS/RRMS in the whole
blood NGS study. While the vast majority of patients
with CIS/RRMS were untreated, most patients with
NMOSD were treated with immunotherapy, reflecting
the more severe course of NMOSD compared to MS [8].
MiRNA profiles in serum
Intrigued by recent findings suggesting that non-cell-
associated miRNAs in plasma may be capable of differenti-
ating between different stages of MS [26], we investigated
whether miRNA profiles in serum may have a similar diag-
nostic value. We thus analyzed miRNA profiles in sera of
patients with NMOSD (n = 20), CIS/RRMS (n = 20), and
healthy controls (n = 20) by genome-wide sequencing of
all miRNAs on the Illumina HiSeq2000 platform. The raw
data were pre-processed as described in the “Methods”
section and normalized using quantile normalization.
Table 1 Demographic and clinical characteristics of the patients with NMOSD and CIS/RRMS as well as of healthy controls included
in this study
Serum (NGS)
NMOSD (n = 20) CIS/RRMS (n = 20; 16/4) Healthy controls (n = 20) p valuea
Females/males (% female) 18/2 (90) 13/7 (65) 13/7 (65) 0.13
Median age, y (range) 49.5 (18–75) 33 (20–41) 32 (21–42) 0.004
Median EDSS (range) 4 (1–9) 1.25 (0–2.5) – –
Immunotherapy (number) AZA (7)
AZA + S (2)
MTX + Quensyl (1)
GLAT (1)
RTX (6)
MMF (1)
None (2)
Interferon-beta (1)
none (19)
– –
Whole blood (NGS)
NMOSD (n = 11) CIS/RRMS (n = 60; 50/10)b Healthy controls (n = 43)c p value
Females/males (% female) 10/1 (91) 38/22 (63) 23/20 (53.5) 0.07
Median age, y (range) 34 (21–75) 31.5 (19–50) 60 (21–83) 0.0003
Median EDSS (range) 4 (1–9) 1.5 (0–3.5)d – –
Immunotherapy AZA (3)
AZA + S (1)
MTX + Quensyl (1)
GLAT (1)
RTX (4)
None (1)
Interferon-beta (1)
None (59)
– –
qRT-PCR validation study
NMOSD (n = 19) CIS/RRMS (n = 19; 15/4) – p value
Females/males (% female) 17/2 (85) 17/2 (85) – 1.0
Median age, y (range) 50 (21–75) 41 (23–51) – 0.1
Median EDSS (range) 3.75 (1–9) 2 (0–3.5) – –
Immunotherapy (number) AZA (7)
AZA + S (2)
MTX + Quensyl (1)
GLAT (1)
RTX (5)
MMF (1)
None (2)
GLAT (2)
Interferon-beta (4)
None (13)
– –
NGS next-generation sequencing, y years, EDSS expanded disability status scale, AZA azathioprine, AZA + S azathioprine and corticosteroids, MTX methotrexate,
GLAT glatiramer acetate, RTX rituximab, MMF mycophenolate mofetil, CIS clinically isolated syndrome, RRMS relapsing-remitting multiple sclerosis, NMOSD neuro-
myelitis optica spectrum disorder
aGender distribution was assessed by 2 × 3 or 2 × 2 Fisher exact test and age differences by Kruskal-Wallis or Mann-Whitney tests
bForty-four of the 60 patients with CIS/RRMS included in this work were recruited in the present study and 16 miRNA expression profiles were from a previous
work [25]
cBlood miRNA profiles from the 43 healthy controls were obtained in two previous projects (n = 21 from Keller et al. [25] and n = 22 from Leidinger et al. [29])
dEDSS values were only available for the 44 patients recruited in the present study
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Additionally, we excluded very lowly (less than 100 reads)
and very highly abundant miRNAs (>50,000 reads). Taken
all three groups together, this identified 286 miRNAs stably
expressed in serum. These miRNAs are listed with the re-
spective mean value, median value, and standard deviation
in the three groups in Additional file 1. After removing
duplicated mature miRNAs from different precursors, 261
expressed miRNAs remained. We next carried out ANOVA
to identify miRNAs, which are differently expressed in one
of the three groups. As presented in Fig. 1, this revealed 18
miRNAs with significantly different expression levels in one
of the three groups (raw p value <0.05). However, given the
large number of miRNAs analyzed, none of the reported
miRNAs remained significant after correction for multiple
testing. Nevertheless, several miRNAs showed interesting
patterns. The two most significant miRNAs, hsa-miR-410-
3p (raw p = 0.0005) and hsa-miR-16-2-3p (raw p = 0.004),
are shown as box plots in Fig. 2. While hsa-miR-410-3p
was lower in NMOSD (average of 12 counts) than in CIS/
RRMS (average of 19 counts) and controls (average of 36
counts), hsa-miR-16-2-3p was higher in NMOSD (average
of 207 counts) than in CIS/RRMS (average of 162 counts)
and controls (average of 124 counts).
To identify differentially expressed miRNAs, which dis-
criminate between two groups, we next carried out pair-
wise comparisons using t tests. When comparing healthy
controls vs. CIS/RRMS and healthy controls vs. NMOSD,
we found 15 and 26 significantly different miRNAs (raw
p values of two-sided t tests <0.05), respectively. Compari-
son of CIS/RRMS vs. NMOSD detected 18 significantly
different miRNAs. The respective miRNAs are listed in
Fig. 1 (lower part). However, again, none of the miRNAs
remained significant after correction for multiple testing.
Detailed information on the pairwise comparisons including
raw and adjusted p values as well as AUC values for all
discovered serum miRNAs including the duplicates from
different precursors are provided in Additional file 2.
MiRNA profiles in whole blood
Compared to the results for serum outlined above, we
previously had observed more significant results in our re-
search on miRNA profiles in whole blood of patients with
CIS/RRMS and healthy controls [10, 12, 25]. Thus, we
went on to carry out miRNA sequencing in whole blood
samples. In this analysis, we included 11 patients with
NMOSD, 60 patients with CIS/RRMS, and 43 healthy
Fig. 1 Synopsis of results of the serum NGS study. MiRNA expression profiles were compared in sera of 20 patients with NMOSD, 20 patients with
CIS/RRMS, and 20 healthy controls. The upper part of the figure lists the 18 miRNAs with significant unadjusted p values as detected by a three-group
comparison by ANOVA. The lower part lists the results of two-group comparisons between the different groups. CIS clinically isolated syndrome, RRMS
relapsing-remitting multiple sclerosis, NMOSD neuromyelitis optica spectrum disorder, ANOVA analysis of variance
Keller et al. Journal of Neuroinflammation  (2015) 12:196 Page 5 of 12
controls. Raw miRNA expression data were processed as
described in the “Methods” section. In the whole blood
samples, we detected, in total, 477 miRNAs corresponding
to 416 unique mature miRNAs after excluding duplicated
mature miRNAs from different precursors. Of these, 222
were also detected in serum as shown in the Venn dia-
gram in Fig. 3a. In analogy to the approach pursued for
serum miRNAs, we next searched for miRNAs in whole
blood that differ in one of the three groups using ANOVA.
This computation identified 211 miRNAs (corresponding
to 180 unique mature miRNAs after removing duplicates
from different precursors), which were significantly altered
in one of the three groups prior to adjustment for multiple
testing. Of these, 178 remained significant (p < 0.05) after
adjustment for multiple testing. The 477 blood-borne
miRNAs are listed with the respective mean value, me-
dian value, and standard deviation in the three groups
in Additional file 3.
Since for the serum analysis no significant miRNAs
remained after adjustment for multiple testing, we com-
pared the significant miRNAs for blood and serum prior
to adjustment. Remarkably, of the 18 miRNAs found to be
different (raw p < 0.05) among the three groups by
ANOVA in serum, seven miRNAs were likewise discov-
ered in the ANOVA of blood samples, as detailed in
Fig. 3b. The two most significant miRNAs in the whole
blood ANOVA, hsa-miR-1180-3p (adjusted p value 10−12)
and hsa-miR-424-3p (adjusted p value 10−10), are shown
as boxplots in Fig. 3c. Both of these miRNAs were higher
in patients with NMOSD than in patients with CIS/RRMS
and healthy controls.
Next, we calculated significant values for the pairwise
comparison of whole blood miRNAs in patients with
NMOSD and CIS/RRMS. This identified 176 significant
miRNAs prior to adjustment and still as much as 115
significant (p < 0.05) miRNAs following adjustment for
multiple testing. The most significantly different miRNA
was hsa-miR-30b-5p, which showed a 2.8-fold upregula-
tion in CIS/RRMS vs. NMOSD patients with correspond-
ing raw and adjusted p values of 3 × 10−9 and 8 × 10−7 and
an AUC value of 0.9 (see Additional file 4 for details).
In the comparison of NMOSD vs. healthy controls, 190
miRNAs were discovered as differentially expressed prior
to adjustment for multiple testing. Following adjustment,
still 141 miRNAs remained significant. Interestingly, 92 of
those miRNAs were significantly higher in healthy con-
trols. Among the top 25 miRNAs, just a single miRNA,
hsa-miR-425-5p, was higher in NMOSD as compared to
healthy controls. The most dysregulated miRNA was hsa-
miR-15b-3p. This miRNA was more than threefold more
abundant in controls resulting in raw and adjusted p values
of 6 × 10−12 and 3 × 10−9, respectively, and an AUC value
of 0.98 (see Additional file 4 for details). Of note, hsa-miR-
15b-3p was also the second most significant miRNA in the
comparison of NMOSD vs. CIS/RRMS.
Finally, a comparison of patients with CIS/RRMS and
healthy controls revealed 112 miRNAs that were signifi-
cantly dysregulated between the two groups. Following
adjustment for multiple testing, 44 miRNAs remained sig-
nificant. Here, the most dysregulated miRNA was hsa-miR-
425-3p. This miRNA was threefold higher in CIS/RRMS
patients, resulting in raw and adjusted p values of 3 × 10−14
and 2 × 10−12, respectively. The corresponding AUC value
was 0.89. All pairwise comparisons are provided with all
raw as well as adjusted p values, fold changes, and AUC
values in Additional file 4.
For a graphical representation of the extent and direc-
tion of whole blood miRNA dysregulation between the
different groups, we calculated volcano plots for all three
pairwise comparisons, showing the log2 fold differences
Fig. 2 Expression levels of the two most significantly different serum miRNAs. The absolute expression levels of the two most significantly
deregulated serum miRNAs, hsa-miR-410-3p and hsa-miR-16-2-3p, in the three-group comparison of patients with NMOSD, CIS/RRMS, and healthy
controls by ANOVA are shown as boxplots. CIS clinically isolated syndrome, RRMS relapsing-remitting multiple sclerosis, NMOSD neuromyelitis
optica spectrum disorder
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of the average miRNA expression between groups on the
x-axis and the negative decade logarithm of the p value on
the y-axis. Overall, this demonstrated that more miRNAs
were higher expressed in patients with CIS/RRMS than in
patients with NMOSD (Fig. 4a). Indeed, setting a raw
p value threshold of 10−3, 45 miRNAs were higher in CIS/
RRMS than in NMOSD (upper right part of Fig. 4a), while
only five miRNAs were higher in NMOSD than in CIS/
RRMS (upper left part of Fig. 4a). Similarly, at a p value
threshold of 10−3, more miRNAs had higher expression
levels in healthy controls than in NMOSD patients (59 vs.
20; Fig. 4b). In contrast, in the comparison of CIS/RRMS
and healthy controls, 15 miRNAs showed higher levels in
CIS/RRMS patients but only 5 miRNAs were higher in
controls (Fig. 4c).
qRT-PCR validation
We next aimed to validate the findings obtained in the
whole blood NGS study by qRT-PCR. As the main goal
of this work was to identify miRNAs that discriminate
between patients with NMOSD and CIS/RRMS, we vali-
dated the whole blood NGS findings for these two pa-
tient groups. We included 19 patients with NMOSD and
19 patients with CIS/RRMS in the qRT-PCR study. One
NMOSD sample had to be excluded because the amount
of RNA was insufficient. Thus, a total of 18 patients with
NMOSD and 19 patients with CIS/RRMS samples could
be analyzed by qRT-PCR. We chose 10 miRNAs for the
qRT-PCR validation study. Besides the three most signifi-
cantly different miRNAs in the two-group comparison
between patients with NMOSD and CIS/RRMS, hsa-miR-
30b-5p, hsa-miR-15b-3p, and hsa-miR-576-5p, we selected
further miRNAs with a range of different expression levels:
hsa-miR-660-5p, hsa-let-7a-5p, hsa-miR-101-3p, hsa-miR-
144-5p, hsa-miR-21-5p, and hsa-miR-215-5p. While all of
these nine miRNAs were lower in patients with NMOSD
than in patients with CIS/RRMS in the whole blood NGS
study, we also included one miRNA (hsa-miR-484) with a
A B
C
Fig. 3 Overview of results from miRNA expression profiling in whole blood. a Venn diagram showing the overlap of all miRNAs detected in
serum and whole blood after removal of duplicated mature miRNAs. b Venn diagram showing the overlap of miRNAs found to be deregulated in
serum and whole blood (raw p values <0.05) in the three-group comparison of patients with NMOSD, CIS/RRMS, and healthy controls by ANOVA.
c The absolute expression levels of the two most significantly deregulated whole blood miRNAs, has-miR-1180-3p and has-miR-424-3p, in the
three-group comparison (ANOVA) of patients with NMOSD, CIS/RRMS, and healthy controls are shown as boxplots. CIS clinically isolated syndrome,
RRMS relapsing-remitting multiple sclerosis, NMOSD neuromyelitis optica spectrum disorder, ANOVA analysis of variance
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moderately higher expression in NMOSD as compared to
CIS/RRMS. Results of the qRT-PCR validation are shown
in Fig. 5. The qRT-PCR study clearly confirmed the lower
expression of hsa-miR-30b-5p, hsa-miR-15b-3p, hsa-miR-
576-5p, hsa-miR-660-5p, hsa-let-7a-5p, hsa-miR-101-3p,
hsa-miR-144-5p, hsa-miR-21-5p, and hsa-miR-215-5p in
whole blood in patients with NMOSD as compared to pa-
tients with CIS/RRMS. In contrast to the whole blood
NGS study, hsa-miR-484 levels were slightly, albeit not sig-
nificantly, lower in patients with NMOSD compared to pa-
tients with CIS/RRMS in the qRT-PCR study. Except for
let-7a-5p, hsa-miR-144-5p, and hsa-miR-484, all differences
were significant (t test). Since the data were not normally
distributed in all cases, we also calculated p values with the
non-parametric Mann-Whitney test, which revealed the
same results.
Because the miRNAs validated in the qRT-PCR study
may represent potential candidates for clinical applica-
tions, we used the miRNACon tool, which we developed
with the aim to discover potentially confounding variables
on miRNA expression levels, to study potential confound-
ing influences of age and gender on the expression levels
of these miRNAs. This analysis demonstrated that the nine
miRNAs in the signature are not dependent on gender,
and just one single miRNAs showed an age dependence,
namely hsa-miR-101-3p. The results of the miRNACon
analysis are presented in Additional file 5.
Enrichment analysis of miRNAs
To discover potential enrichment of miRNAs on pathways,
in functional categories, or with respect to diseases, tissues,
or cell types, we employed our miRNA set enrichment tool
miEAA, which is freely available at http://www.ccb.uni-
saarland.de/mieaa_tool/. Altogether, we thereby explored
over 15,000 functional miRNA sets and analyzed whether
the 141 miRNAs from the comparison NMOSD vs. healthy
controls and the 115 significant miRNAs from the compari-
son NMOSD vs. CIS/RRMS accumulate in certain categor-
ies. Categories were considered to be enriched if they
contained at least two miRNAs and had an adjusted p value
below 0.05. The miRNA sets included in this analysis are
partially direct miRNA sets but likewise contain sources
from databases that also include miRNA target genes, such
as miRWalk.
For the 141 miRNAs differentially expressed in NMOSD
patients as compared to controls, we found the most sub-
stantial enrichment in CD15+ cells (adjusted p value
4.9 × 10−16; expected 25 miRNAs by chance, found 62
miRNAs). Furthermore, these miRNAs were likewise sig-
nificantly enriched in CD14+, CD56+, CD3+, and CD19+
cells. Regarding disease associations, we found many unspe-
cific hits including several cancer entities but also auto-
immune diseases (expected 11, discovered 22, p = 0.005)
and neurodegenerative diseases (data source KEGG: ex-
pected 30, discovered 44, p = 0.0006; data source miRWalk:
A B C
Fig. 4 Volcano plots demonstrating different miRNA expression levels in whole blood in two-group comparisons. Volcano plots showing the log2
fold differences of the average miRNA expression in whole blood on the x-axis and the negative decade logarithm of the unadjusted p value on
the y-axis. a Patients with NMOSD vs. patients with CIS/RRMS, b patients with NMOSD vs. healthy controls, c patients with CIS/RRMS vs. healthy
controls. The horizontal lines indicate a p value of 10−3. CIS clinically isolated syndrome, RRMS relapsing-remitting multiple sclerosis, NMOSD neuromyelitis
optica spectrum disorder
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expected 17, discovered 28, p = 0.005). Regarding biochem-
ical pathways, we found very strong enrichment of several
paths from KEGG and Biocarta, many of them connected
to the immune system. The most significant pathways were
calcium signaling (KEGG) and NO2IL12 (Biocarta). Other
examples include the T helper and B cell pathway (Bio-
carta) or the IFNG pathway (Biocarta). Additionally, we
discovered six target genes that were significantly enriched:
IRAK1, FBXW2, SMARCD1, HMMR, SCMH1, and BAZ1B.
All results of this in silico enrichment analysis are provided
in Additional file 6.
For the 115 miRNAs from the comparison NMOSD vs.
CIS/RRMS patients, we analogously carried out the en-
richment analysis. Regarding cell types, again, CD15+ cells
showed highest enrichment (adjusted p value 8.5 × 10−11;
expected 19 miRNAs by chance, found 46 miRNAs),
followed by CD14+, CD56+, CD19+, and CD3+ cells. With
respect to diseases, we again found many unspecific hits
but still, autoimmune diseases (expected 9, discovered 19,
p = 0.006) and neurodegenerative diseases (data source
KEGG: expected 24, discovered 35, p = 0.003; data source
miRWalk: expected 13, discovered 25, p = 0.003) were sig-
nificant. With respect to pathways, calcium signaling was
still significant, but in this analysis, it just ranked on pos-
ition 42. The most significant paths were the LDL and the
ETS pathways from Biocarta. The T helper, B cell, IL17,
and IL6 pathways were among the significant paths (Bio-
carta) as well. We also found a total of nine target genes
that were significantly enriched: TNRC6B, RPL4, BAZ1B,
IRS4, APP, SPATA2, NCKAP5L, TRIM33, and AGO2.
Only BAZ1B has already been discovered in the first en-
richment analysis. All results of this analysis are detailed
in Additional file 7.
For the serum samples we had not discovered significant
miRNAs in the ANOVA following adjustment for multiple
testing. Nevertheless, we assessed whether we could dis-
cover potential enrichment of the most significant miR-
NAs prior to adjustment in an exploratory fashion. In
order to minimize a potential bias due to different miRNA
set size, we selected the 178 most significant miRNAs,
matching the number of blood-borne miRNAs. Here, our
analysis did not yield any significant results, providing fur-
ther evidence for the higher relevance of miRNAs in
whole blood.
Discussion
Here, we report the results of a systematic comparative
study of both miRNA profiles in serum and whole blood of
patients with NMOSD, CIS/RRMS, and healthy controls.
The key findings of this work are (i) an absence of any sig-
nificantly different serum miRNAs after adjustment for
multiple testing, (ii) the detection of a number of highly
significantly deregulated miRNAs in whole blood in the
three-group and the two-group comparisons of patients
with NMOSD, CIS/RRMS, and healthy controls, (iii) the
validation of selected whole blood miRNAs deregulated
Fig. 5 qRT-PCR validation study of differentially expressed whole blood miRNAs in patients with NMOSD and CIS/RRMS. The figure shows the
absolute delta CT (target miRNA—housekeeping RNA (RNU48)) values for 10 miRNAs in the groups of patients with NMOSD (n = 18) and CIS/
RRMS (n = 19). Note that higher delta CT values indicate lower expression levels. Bars represent the mean ± standard deviation. Expression levels
of miRNAs indicated in bold were significantly different (p < 0.05). CIS clinically isolated syndrome, RRMS relapsing-remitting multiple sclerosis,
NMOSD neuromyelitis optica spectrum disorder
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between patients with NMOSD and CIS/RRMS by qRT-
PCR, and (iv) the identification of cell types, in particular,
CD15+ neutrophils and eosinophils, and pathways in which
deregulated whole blood miRNAs are enriched.
While miRNA expression profiles were previously often
investigated in whole blood or leukocyte subsets, recent
studies suggested that also non-cell-associated miRNAs cir-
culating in blood and measured in serum or plasma could
serve as biomarkers for cancer, inflammation, and neuro-
logical diseases, including MS [26, 34–37]. Therefore, we
initially set out to analyze miRNA expression profiles in
serum of patients with NMOSD, CIS/RRMS, and healthy
controls. Because the pathogenesis of AQP4 antibody-
negative NMOSD spectrum disorders (NMOSD) may be
different from that of AQP4 antibody-positive NMOSD
[8, 38], we aimed to reduce inhomogeneity within the
group of patients with NMOSD and purposefully included
only AQP4 antibody-positive patients in our study. The
261 miRNAs detected across all three groups in the serum
NGS study confirm that miRNAs are present over a broad
range of expression levels in human serum and define the
landscape of human serum miRNAs. Likewise, the detect-
ability of miRNAs in serum suggests that these miRNAs
could in principle serve as disease biomarkers. Neverthe-
less, since none of the observed differences of the expres-
sion levels of serum miRNAs in the three-group and the
two-group comparisons remained significant after correc-
tion for multiple testing, the potential of serum miRNA
profiles as biomarkers for differentiation of NMOSD, CIS/
RRMS, and healthy controls appears questionable.
Because more miRNAs were detectable in whole blood
(n = 416) than in serum (n = 261), not all miRNAs expressed
in blood cells appear to be released into serum. Alterna-
tively, the concentration of some miRNAs in serum could
also be below the detection limit of NGS. Interestingly,
few miRNAs were only detected in serum but not in whole
blood, compatible with an enhanced secretion of these
miRNAs into serum.
MiRNA profiling by NGS in whole blood samples identi-
fied a set of differentially expressed miRNAs in the three-
group comparison and in the two-group comparisons,
which remained significant after correction for multiple
testing. This suggests that whole blood is a more appropri-
ate biospecimen for analyses of miRNAs as biomarkers for
neuroinflammatory diseases than serum. Indeed, the high
AUC values of the miRNAs, which separated best between
patients with NMOSD and CIS/RRMS (hsa-miR-30b-5p;
AUC 0.9) and patients with NMOSD and healthy controls
(hsa-miR-15b-3p; AUC 0.98), indicate that the expression
levels of these miRNAs in whole blood may potentially
discriminate patients with NMOSD from patients with
CIS/RRMS and healthy controls. Interestingly, hsa-miR-
15b-3p was not only the most significantly different
miRNA when comparing NMOSD and healthy controls
but was also the miRNA that discriminated second best
between NMOSD and CIS/RRMS. Downregulated expres-
sion of miR15b-3p in whole blood may thus be specifically
associated with NMOSD. In both comparisons, NMOSD
vs. healthy controls and NMOSD vs. CIS/RRMS, clearly
more miRNAs were lower in NMOSD than in CIS/RRMS
or healthy controls (Fig. 4a, b) among the significantly
deregulated miRNAs. Although the reasons for the down-
regulation of a number of miRNAs in NMOSD are un-
clear, this again differentiates NMOSD from CIS/RRMS,
where most of the significantly deregulated miRNAs were
higher in patients than healthy controls. Altogether, the
different miRNA profiles in patients with NMOSD and
CIS/RRMS further support the notion that NMOSD and
CIS/RRMS represent different diseases.
The different miRNA expression levels in patients with
NMOSD and CIS/RRMS obtained in the whole blood
NGS study could be confirmed by qRT-PCR validation
for 9 out of 10 exemplarily chosen miRNAs, 7 of which
(including hsa-miR-15b-3p) reached statistical signifi-
cance. Findings from NGS were thus reproducible by a
different method, underscoring the validity of the NGS
results. Nevertheless, the absolute fold differences of the
top ranking miRNAs between the different groups in the
NGS and qRT-PCR studies were only about threefold,
and the standard deviations between groups overlapped.
Further studies in independent cohorts will therefore be
mandatory to corroborate the value of the miRNAs identi-
fied in this work as diagnostic biomarkers for NMOSD.
In addition to their potential role as biomarkers, the
miRNAs found to be deregulated in NMOSD could be of
relevance in the pathophysiology of NMOSD. An in silico
enrichment analysis demonstrated, for both comparisons
NMOSD vs. CIS/RRMS and NMOSD vs. controls, a highly
significant enrichment of the miRNAs deregulated in
NMOSD in immune cells (CD15+, CD14+, CD56+, CD19+,
and CD3+ cells) of relevance for NMOSD. While enrich-
ment in these cells was not unexpected as we studied
whole blood containing immune cells, quite remarkably,
for both comparisons, the most significant enrichment was
observed for CD15+ cells, i.e., neutrophils and eosinophils
[39, 40]. In contrast to MS, neutrophils and eosinophils are
frequently found in the cerebrospinal fluid of patients with
NMOSD and are known to play an important role in the
pathogenesis of NMOSD lesions [41–43]. Our findings are
thus consistent with an altered function of neutrophils and
eosinophils in NMOSD and suggest that miRNAs may be
involved in the pathophysiology of neutrophils/eosinophils
in NMOSD. However, as the functional effects of the miR-
NAs with altered expression profiles in NMOSD are just
partially understood, the precise molecular mechanisms
underlying a potential role of these miRNAs in NMOSD
and in the regulation of neutrophils/eosinophils remain to
be explored.
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Limitations of this work are the limited number of pa-
tients with NMOSD in the whole blood NGS study and a
possible confounding role of immunotherapy in NMOSD
patients. However, the results obtained in the whole blood
NGS study could clearly be confirmed in a larger number
of patients with NMOSD in the qRT-PCR validation study,
suggesting that findings obtained in a smaller number of
patients are reproducible in larger cohorts. Furthermore,
clinical characteristics of the patients included in this study
could influence miRNA expression levels, too. While this
study was not specifically designed to investigate the associ-
ation of clinical characteristics with miRNA expression
levels, exploratory analyses did not show an association of
disease duration, the number of previous relapses, and the
time since last relapse with whole blood miRNA expression
levels in patients with CIS/RRMS (clinical data available for
n = 44 patients) or NMOSD (n = 11).
Among the strengths of this study is the application of
NGS technology, which in contrast to more traditional
methods of miRNA profiling (miRNA microarrays and
qRT-PCR), that are necessarily restricted to a limited num-
ber of miRNA targets, has the advantage of allowing for the
unbiased detection of all known and even novel miRNAs.
Thus, NGS is currently one of the most comprehensive
methodological approaches to determine miRNA expres-
sion profiles [44, 45]. Another strength is that p values were
rigorously adjusted for multiple testing, which reduces the
risk of false positive findings inherent to the high number
of statistical comparisons typically performed in miRNA
profiling studies [44].
Conclusions
In conclusion, this study identifies a set of differentially
expressed miRNAs in whole blood, which may discriminate
patients with NMOSD from patients with CIS/RRMS and
healthy controls. In contrast, miRNAs expressed in serum
do not appear to be promising diagnostic biomarkers for
NMOSD. Although the confirmation of the NGS results for
9 out of 10 exemplarily chosen miRNAs by qRT-PCR ar-
gues for the robustness of the findings, it will be important
to reproduce our results in independent patient cohorts. En-
richment of miRNAs differentially expressed in NMOSD in
CD15+ neutrophils/eosinophils suggests that miRNAs could
be involved in the regulation of neutrophils/eosinophils in
NMOSD, immune cell subsets that have previously indeed
been implicated in the immunopathogenesis of that condi-
tion [41–43]. Future studies should clarify the molecular
mechanisms through which the miRNAs identified in this
work may contribute to the pathophysiology of NMOSD.
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